Lincocin (Lincomycin Hydrochloride)

Lincomycin Hydrochloride inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This blocks the translocation step of peptide chain elongation, halting bacterial growth and allowing the immune system to clear the infection.

The dosage of Lincocin is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal and hepatic function, and route of administration. Only a qualified healthcare professional should set the dosing regimen.

Safety data for Lincomycin Hydrochloride in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Lincocin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Lincocin (lincomycin) is a lincosamide similar to clindamycin but generally has a broader spectrum against certain anaerobes and fewer drug‑interaction concerns. However, clindamycin is often preferred for its longer half‑life and oral formulation, while lincomycin is mainly used intravenously or intramuscularly.

Lincocin should be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and do not freeze or shake the solution. This preserves potency and sterility.

Lincocin is supplied as an injectable solution for intramuscular or intravenous administration. The route, infusion rate, and dilution are determined by the prescribing clinician and should follow aseptic technique and local guidelines.

Serious risks include severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, hepatotoxicity, and hematologic abnormalities like neutropenia or agranulocytosis. Patients should be monitored for signs of these conditions during therapy.

Lincocin should be avoided in patients with a known hypersensitivity to lincomycin, other lincosamides, or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, and it is generally contraindicated in pregnancy unless clearly needed.